Liaoning Chengda Biological Co., Ltd. (hereinafter referred to“Company”) Received the Drug Clinical Trial Approval Notice issued by the State Drug Administration (Notice No:2022LP01324), approved live attenuated varicella vaccine for clinical trials.

    The company's declaration of live attenuated varicella vaccine, the use of varicella-Herpes zoster virus inoculation of human diploid cells, after culture, harvest, clarification, add stabilizer freeze-dried, the vaccine can make the body produce memory immune response, stimulate the body to produce anti-varicella-Herpes zoster virus immunity for the prevention of chickenpox. This vaccine uses the production process of ultrasonic technology outside the cell factory, and is currently the first to be used in similar domestic competitors, which can greatly increase production capacity, with large-scale production, product safety better than similar products and many other advantages. Varicella virus is highly contagious, and the main route of transmission is respiratory droplets or direct contact. After the virus infects the human body, the first local lymph node proliferation in the nasopharynx, then invades the blood to spread to the whole body, causing various organ lesions, the formation of herpes. Blisters are also common in the oropharynx, respiratory tract, gastrointestinal tract, conjunctiva, and mucosal surfaces. People of any age can get chickenpox-Herpes zoster virus, especially in infants and preschool, school-age children more incidence.

The company's declaration of live attenuated varicella vaccine not only helps the company to enrich the product research and development pipeline, but also lays the foundation for the subsequent development of other products.